Portions of this exhibit marked [*] are omitted and are requested to be treated confidentially. MANUFACTURING AND SUPPLY AGREEMENTQuality Agreement • February 28th, 2012 • Salix Pharmaceuticals LTD • Pharmaceutical preparations
LICENSE AGREEMENT BETWEEN Q-MED SCANDINAVIA INC. AND Q-MED ABLicense Agreement • February 28th, 2012 • Salix Pharmaceuticals LTD • Pharmaceutical preparations • New York
This License Agreement is made and entered into this 2nd day of June, 2009 by and between Q-MED AB, a corporation of organized under the laws of the Kingdom of Sweden with corporate registration number 556258-6882 (“Q-Med”), and Q-MED SCANDINAVIA INC., a corporation organized under the laws of the State of Delaware (“QMS”). Each of Q-Med and QMS shall be referred to herein as a “Party” and collectively as the “Parties.”
STOCK PURCHASE AGREEMENT between SALIX PHARMACEUTICALS, INC., as Buyer OCEANA THERAPEUTICS LLC, as Seller with respect to all of the outstanding stock of OCEANA THERAPEUTICS, INC. Dated as of November 8, 2011Stock Purchase Agreement • February 28th, 2012 • Salix Pharmaceuticals LTD • Pharmaceutical preparations • New York
This STOCK PURCHASE AGREEMENT, dated as of November 8, 2011 (this “Agreement”), is made by and among Salix Pharmaceuticals, Inc., a California corporation (“Buyer”), and Oceana Therapeutics LLC, a Delaware limited liability company (“Seller”). Capitalized terms used herein shall have the meanings assigned to such terms in the text of this Agreement or in Section 8.1.
SUPPLY AGREEMENT BETWEEN CETACEA LIMITED AND Q-MED ABSupply Agreement • February 28th, 2012 • Salix Pharmaceuticals LTD • Pharmaceutical preparations • New York
This Supply Agreement (this “Agreement”) is entered into as of June 2, 2009 between CETACEA LIMITED, a limited company organized under the laws of the Republic of Ireland (“Ireland”), and Q-MED AB, a company organized under the laws of the Kingdom of Sweden with corporate registration number 556258-6882 (“Q-Med”). Each of Q-Med and Ireland shall be referred to herein as a “Party” and collectively as the “Parties.”
LICENSE AGREEMENT BETWEEN CETACEA LIMITED AND Q-MED ABLicense Agreement • February 28th, 2012 • Salix Pharmaceuticals LTD • Pharmaceutical preparations • New York
This License Agreement is made and entered into this 2nd day of June, 2009 by and between Q-MED AB, a corporation of organized under the laws of the Kingdom of Sweden with corporate registration number 556258-6882 (“Q-Med”), and CETACEA LIMITED, a limited company organized under the laws of the Republic of Ireland (“Ireland”). Each of Q-Med and Ireland shall be referred to herein as a “Party” and collectively as the “Parties.”
STOCK PURCHASE AGREEMENT between Q-MED AB and OCEANA THERAPEUTICS, LLC regarding the purchase and sale of all of the outstanding capital stock of Q-MED SCANDINAVIA INC. dated as of April 22, 2009Stock Purchase Agreement • February 28th, 2012 • Salix Pharmaceuticals LTD • Pharmaceutical preparations • New York
STOCK PURCHASE AGREEMENT, dated as of April 22, 2009 (the “Agreement”), between Oceana Therapeutics, LLC, a Delaware limited liability company (“Buyer”), and Q-Med AB, a corporation organized under the laws of Swede (“Seller”), Buyer and Seller are sometimes referred to herein as the “Parties” and individually as a “Party”).
SUPPLY AGREEMENT BETWEEN Q-MED SCANDINAVIA INC. AND Q-MED ABSupply Agreement • February 28th, 2012 • Salix Pharmaceuticals LTD • Pharmaceutical preparations • New York
This Supply Agreement (this “Agreement”) is entered into as of June 2, 2009 between Q-MED SCANDINAVIA INC., a corporation organized under the laws of Delaware (“QMS”), and Q-MED AB, a company organized under the laws of the Kingdom of Sweden with corporate registration number 556258-6882 (“Q-Med”). Each of Q-Med and QMS shall be referred to herein as a “Party” and collectively as the “Parties.”
